Mapping symptoms, circuits and treatment outcomes: Development of a personalized clinical imaging system and its initial validation in depression and anxiety
The lack of biomarkers to inform antidepressant selection is a key challenge in personalized depression treatment. This work identifies candidate biomarkers by building deep learning predictors of individual treatment outcomes using reward processing measures from functional magnetic resonance imaging, clinical assessments, and demographics. Participants in the EMBARC (Establishing Moderators and Biosignatures of Antidepressant Response in Clinical Care) study (n = 222) underwent reward processing task-based functional magnetic resonance imaging at baseline and were randomized to 8 weeks of sertraline (n = 106) or placebo (n = 116). Subsequently, sertraline nonresponders (n = 37) switched to 8 weeks of bupropion. The change in Hamilton Depression Rating Scale was measured after treatment. Reward processing, clinical measurements, and demographics were used to train treatment-specific deep learning models.

These findings demonstrate the utility of reward processing measurements and deep learning to predict antidepressant outcomes and to form multimodal treatment biomarkers.
Date: 8 March 2022, 15:00 (Tuesday, 8th week, Hilary 2022)
Venue: via Zoom (please send an email to organiser or consider subscribing to mailing list here: web.maillist.ox.ac.uk/ox/info/ai4mch)
Speaker: Professor Albert Montillo (The University of Texas Southwestern Medical Center)
Organising department: Department of Psychiatry
Organiser: Dr Andrey Kormilitzin (University of Oxford)
Organiser contact email address: andrey.kormilitzin@psych.ox.ac.uk
Host: Dr Andrey Kormilitzin (University of Oxford)
Part of: Artificial Intelligence for Mental Health Seminar Series
Booking required?: Not required
Booking email: andrey.kormilitzin@psych.ox.ac.uk
Audience: Public
Editor: Andrey Kormilitzin